A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus

Annals of Neurology
L Averbuch-HellerR J Leigh

Abstract

We conducted a double-blind crossover trial comparing gabapentin (up to 900 mg/day) to baclofen (up to 30 mg/day) as therapy for acquired nystagmus in 21 patients. We measured visual acuity and the nystagmus before, and at the end of, 2 weeks on each medication. For a group of 15 patients with acquired pendular nystagmus (APN), visual acuity improved significantly with gabapentin, but not with baclofen. Gabapentin significantly reduced APN median eye speed in all three planes, but baclofen did so only in the vertical plane. In 10 patients with APN, the reduction of nystagmus with gabapentin was substantial and 8 of these elected to continue taking the drug. In 6 patients with downbeat or torsional downbeat nystagmus, changes in median slow-phase eye speed were less consistent with both drugs, either increasing or decreasing, and being dependent on viewing conditions. Only 1 patient showed consistent reduction of median eye speed, and this was achieved by either drug. Our findings suggest that gabapentin may be an effective treatment for many patients with APN and that occasional patients with downbeat nystagmus will respond to gabapentin or baclofen.

References

Jul 1, 1991·Journal of Neurology, Neurosurgery, and Psychiatry·M DieterichU Büttner
Aug 1, 1986·Journal of Neurophysiology·E ViirreT Vilis
Jun 1, 1983·Annals of Neurology·P J LavinC Ellenberger
Dec 1, 1980·Annals of Neurology·G M HalmagyiD S Zee
Oct 1, 1981·Journal of Neurophysiology·D S ZeeG Gücer
Jan 1, 1994·Annual Review of Neuroscience·R L Macdonald, R W Olsen
Apr 1, 1995·Brain : a Journal of Neurology·L Averbuch-HellerR J Leigh
Jan 1, 1994·International Review of Neurobiology·D D Mott, D V Lewis
Mar 14, 1994·Neuroscience Letters·J D Kocsis, O Honmou
Jan 1, 1996·Annals of Neurology·O A PetroffR H Mattson
Apr 1, 1996·Brain : a Journal of Neurology·L I LopezP Rudge
Jan 1, 1997·Journal of Neurology·M StarckM Dieterich
Apr 1, 1996·Neuro-ophthalmology·J S StahlR J Leigh

❮ Previous
Next ❯

Citations

Apr 3, 1999·Medicinal Research Reviews·J S Bryans, D J Wustrow
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·W OndoJ Jankovic
Jul 18, 2008·Der Nervenarzt·R KallaM Strupp
Jan 22, 2011·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·C Pieh-Beisse, W A Lagrèze
Apr 10, 2007·Journal of Neurology·Marianne Dieterich
Apr 5, 2011·Journal of Neurology·Michael StruppR John Leigh
Mar 20, 2002·Current Neurology and Neuroscience Reports·J S Stahl, R J Leigh
Sep 4, 2007·Current Neurology and Neuroscience Reports·James Corbett
Feb 23, 2012·Current Neurology and Neuroscience Reports·Rebecca Jane McLeanFrank Antony Proudlock
Dec 22, 2004·Current Treatment Options in Neurology·Janet C Rucker
Nov 11, 2011·Current Treatment Options in Neurology·Matthew J Thurtell, R John Leigh
Nov 30, 2000·Current Treatment Options in Neurology·L Averbuch-Heller
Jul 27, 2001·Neurologic Clinics·T Z MovsasN J Volpe
Jan 30, 2004·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A StraubeD Straumann
Sep 25, 2001·The Laryngoscope·Y H Young, T W Huang
Nov 29, 2001·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·J I KimR J Leigh
Nov 26, 2010·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Matthew J Thurtell, R John Leigh
Jul 8, 2011·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Roger KallaMichael Strupp
Sep 13, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A StraubeUNKNOWN European Federation of Neurologic Societies
Oct 26, 1999·Epilepsia·L Magnus
Apr 19, 2002·Annals of the New York Academy of Sciences·R John LeighScott H Seidman
Apr 19, 2002·Annals of the New York Academy of Sciences·David SolomonAnupam Mishra
Mar 25, 2006·The British Journal of Ophthalmology·T SheryI Gottlob
Sep 13, 2006·European Neurology·T HenzeUNKNOWN Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society
Jun 23, 2011·Therapeutic Advances in Neurological Disorders·João Carlos Correia de SaBernd C Kieseier
Jan 11, 2003·CNS Drugs·Timothy C Hain, Mohammed Uddin
Mar 1, 2001·Clinical Drug Investigation·M C MauriG Cerveri
Jul 9, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Aasef G Shaikh
Nov 14, 2013·The Cerebellum·W IlgD Timmann
Dec 3, 2014·Neurologic Clinics·Shin C BehElliot M Frohman
Feb 5, 2016·Expert Review of Ophthalmology·Aasef G Shaikh, Fatema F Ghasia
Apr 1, 2003·Expert Opinion on Investigational Drugs·Bianca A Lauria-Horner, Robert B Pohl
May 17, 2006·Seminars in Ophthalmology·R John Leigh, Sangeeta Khanna
Mar 6, 2008·Seminars in Ophthalmology·Janet C Rucker
May 5, 2010·Expert Opinion on Drug Metabolism & Toxicology·Masatoshi Tomi, Ken-ichi Hosoya
Dec 10, 2013·Physical Medicine and Rehabilitation Clinics of North America·Courtney E Francis
Dec 17, 2010·Journal of Pediatric Ophthalmology and Strabismus·Dean M CestariJoseph F Rizzo
Sep 29, 2011·Annals of the New York Academy of Sciences·Aasef G ShaikhR John Leigh
Oct 13, 2006·Pharmacology & Therapeutics·H Stefan, T J Feuerstein
May 7, 2002·American Journal of Ophthalmology·Robert L TomsakR John Leigh
Feb 7, 2007·Annals of Neurology·Rebecca McLeanIrene Gottlob
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Andreas Straube
Dec 15, 2010·Acta Oto-laryngologica·Doreen HuppertThomas Brandt
Jan 1, 2014·Multiple Sclerosis and Related Disorders·Simon J HickmanIrene Gottlob

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.